For more than 30 years, Sanofi has supported patients with Lysosomal Storage Disorders through its Rare Humanitarian Program, which is the first, the largest and the longest running program of its kind. Tune in to hear more about how Sanofi supports patients across the world even in times of crisis.

Real World Data and Evidence (RWD/RWE) are increasingly being utilized by key decision-makers in the Rare Disease ecosystem. Registries can be one of the most robust vehicles for generating meaningful evidence. Join us to learn more about the diverse world of registries and how they inform our understanding and treatment of rare diseases.

Despite years of medical progress, why have diagnostic delays remained unchanged? The panelists will delve into whether we should address rare diseases one at a time or adopt an omics approach, and how AI-based methods are transforming diagnostics now and in the future. We address what it will take to see widespread adoption of augmented support technologies and how we can expedite this process. Join us for an insightful discussion on the future of rare disease diagnosis, featuring expert perspectives on the challenges, innovations, and necessary steps for transformative change.

Evidence of a therapy's efficacy and safety is crucial for decision making by a patient's physician, but particular problems exist for generating evidence in patients with rare diseases. Tune in to hear more about how new ideas and approaches are changing the way we look at the totality of evidence for rare disease therapies.

The value of real world data and evidence, alongside traditional clinical trial evidence, has been increasingly recognized in the healthcare community. Tune in to hear about how we can incorporate real world data in our decision-making, particularly in the area of rare diseases where data are more difficult to generate